|
EQS-News: STRATEC SE / Key word(s): Conference STRATEC TO PARTICIPATE IN THE 42ND ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE 21.12.2023 / 16:59 CET/CEST The issuer is solely responsible for the content of this announcement. STRATEC TO PARTICIPATE IN THE 42ND ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE Birkenfeld, December 21, 2023 STRATEC SE, Birkenfeld, Germany, (Frankfurt: SBS; Prime Standard, SDAX) will participate in the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024, at the Westin St. Francis in San Francisco, CA, USA. Marcus Wolfinger, Chief Executive Officer of STRATEC SE, will represent the company in a session scheduled at 7:30 am PST (10:30 am EST / 3:30 pm GMT / 4:30 pm CET). The presentation will be webcast live and can be accessed on the company’s website at www.stratec.com in the Investors section under Events & Presentations. A replay of the webcast will be available after the presentation and will remain available for 30 days. ABOUT STRATEC The partners market the systems, software and consumables, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. STRATEC develops its products on the basis of patented technologies. Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the SDAX select index of the German Stock Exchange. FURTHER INFORMATION IS AVAILABLE FROM: 21.12.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Toripalimab by Shanghai Junshi Biosciences for Cervical Cancer: Likelihood of Approval
Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug
November 19, 2023